Novartis' pharma chief has hailed the company's forthcoming heart failure treatment as "the most exciting launch the company has ever had," and now the drugmaker's CEO has declared a "multi-blockbuster" in the making, joining a chorus of analysts who expect billions in annual sales from LCZ696.
Zoetis has embarked on a new mission to identify and quickly address diseases in livestock and companion animals by capitalizing on the latest advances in genetic sequencing and molecular biology. Towards that end, the company is teaming up with the Easter Bush Research Consortium--a group that includes several Scottish academic and scientific institutions--to form a new European research center headquartered in Edinburgh.
Late last year F-star spun out one of its early-stage drugs into a separate "asset-centric" company dubbed F-star Alpha. A group of venture players including Atlas and SR One chipped in $12 million to fund the clinical plans for the HER2-targeting antibody fragment FS102. And now Bristol-Myers Squibb has come along and seized the prize, nabbing a buyout option on the spinout as well as worldwide rights for an upfront and near-term milestone payment of $50 million in a deal that is worth up to $475 million.
Watertown, MA's Syros Pharmaceuticals has banked a massive $53 million Series B to support its innovative approach to treating cancer, targeting the genetic switches responsible for tumor growth.
The Association of Clinical Research Organizations, which represents the world's largest CROs, is putting together a sort of contractors' council to weigh in on the efforts of TransCelerate BioPharma, a nonprofit group run by the biggest names in drug development.
With the goal line for lung cancer in sight at the FDA as it races with an ambitious R&D team at Bristol-Myers Squibb, Merck has grabbed bragging rights to the agency's breakthrough drug designation for the checkpoint inhibitor pembrolizumab (Keytruda) for that golden market opportunity.
Dr. Patrick Soon-Shiong has teamed up with the University of Oxford and others to further the United Kingdom's plan to build the "NASA of biomedicine." Some of the £141 million ($227 million) investment is earmarked for establishing computing infrastructure to support the U.K.'s genomics project.
Amid the rise of antibiotic-resistant superbugs in hospital systems and facilities, scientists at Johns Hopkins are developing a real-time tracking system that could quickly diagnose and monitor antibiotic-resistant bacterial infections.
WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.
In a week during which 23andMe showed results from a clutch of its research programs at the American Society of Human Genetics annual meeting, it also tasked an industry veteran with winning new partnerships.